Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in
reduction in proteinuria in patients with diabetic kidney disease with valsartan as the
comparator, and determine the recommended dose.